Adverse effects and costs of chemotherapy greater than previously thought

August 15, 2006

BOSTON--Researchers at Dana-Farber Cancer Institute and Harvard Medical School have found that breast cancer patients 63 years of age or younger may experience more chemotherapy-related serious adverse effects than reported in clinical trials, according to a new study in the August 16 issue of the Journal of the National Cancer Institute.

Led by Michael J. Hassett, MD, MPH, of Dana-Farber, researchers studied a database of medical claims made by women with newly diagnosed breast cancer who had employer-provided health insurance between January 1998 and December 2002.

"This is the first study, to our knowledge, of chemotherapy-related serious adverse effects in a population-based sample of younger women with breast cancer," said Hassett, who is also an instructor in medicine at Harvard Medical School. "We found that eight chemotherapy-related serious adverse effects may be more common than reported in large clinical trials, and, therefore, these adverse effects may be responsible for more patient suffering and higher health care expenditures than currently predicted."

Doctors often prescribe chemotherapy to eliminate residual cancer cells in women who have undergone surgery for breast cancer. Women who received chemotherapy were more likely to be hospitalized or visit emergency rooms for problems that are typically related to chemotherapy, including fever or infection, low white blood cell or platelet count, nausea, diarrhea, malnutrition, or dehydration.

Researchers studied 7,052 women from a database of claims made to health plans that contract with large employers in the U.S. The group was equally divided into two cohorts of 3,526: those who received chemotherapy within 12 months of their first breast cancer diagnosis, and those who did not.

In addition to more incidents of chemotherapy-related adverse effects, women undergoing chemotherapy for breast cancer also experienced increased healthcare costs: $1,271 more per year for hospitalizations and emergency room visits and $17,617 more per year for ambulatory care than women who did not receive chemotherapy.

Additional contributors of the report are from Dana-Farber and the Harvard School of Public Health.
-end-
The research was funded by grants from the Agency for Healthcare Research and Quality and the National Institutes of Health.

Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.

Dana-Farber Cancer Institute

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.